Abiraterone Tablet, Film Coated
Product Images NDC 82009-140

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Abiraterone (NDC 82009-140). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Quallent Pharmaceuticals Health Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Abiraterone-250mg-120s-container-label (Abiraterone 250mg 120s Container Label)

Abiraterone-250mg-120s-container-label (Abiraterone 250mg 120s Container Label)
This is a prescription medication containing 250 mg of abiraterone acetate per tablet. It is recommended to store the tablets between 15°C to 30°C (59°F to 86°F). The tablets should be swallowed whole and kept out of reach of children. Pregnant women or those who may be pregnant are warned against handling the tablets without gloves. The medication is manufactured by Quallent Pharmaceuticals Health LLC and comes in a package of 120 tablets.*
FDA Label Image

Figure-01 (Abiraterone Figure 01)

Figure-01 (Abiraterone Figure 01)
This is not-readable.*
FDA Label Image

Figure-02 (Abiraterone Figure 02)

Figure-02 (Abiraterone Figure 02)
This data appears to be a comparison between subjects receiving Abiraterone and Placebo in a study where the percentage of subjects without death is evaluated over a period of months from randomization. The graph or data table seems to show the survival rates or outcomes of subjects over time for both Abiraterone and Placebo groups. The information could be useful for analyzing the efficacy of Abiraterone treatment on subjects in comparison to Placebo in terms of survival rate.*
FDA Label Image

Figure-03 (Abiraterone Figure 03)

Figure-03 (Abiraterone Figure 03)
This is a statistical table comparing the subjects without radiographic progression or death between the Abiraterone and Placebo groups over a span of 12 months. The table shows the number of subjects in each group at different points in time.*
FDA Label Image

Abiraterone-figure-04 (Abiraterone Figure 04)

FDA Label Image

Abiraterone-structure (Abiraterone Structure)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.